3-148991648-G-A
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_004130.4(GYG1):c.7+1G>A variant causes a splice donor change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000519 in 1,540,972 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_004130.4 splice_donor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GYG1 | NM_004130.4 | c.7+1G>A | splice_donor_variant | ENST00000345003.9 | NP_004121.2 | |||
GYG1 | NM_001184720.2 | c.7+1G>A | splice_donor_variant | NP_001171649.1 | ||||
GYG1 | NM_001184721.2 | c.7+1G>A | splice_donor_variant | NP_001171650.1 | ||||
GYG1 | XM_017006275.2 | c.-35+1G>A | splice_donor_variant | XP_016861764.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GYG1 | ENST00000345003.9 | c.7+1G>A | splice_donor_variant | 1 | NM_004130.4 | ENSP00000340736 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152116Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000721 AC: 1AN: 138668Hom.: 0 AF XY: 0.0000130 AC XY: 1AN XY: 76694
GnomAD4 exome AF: 0.00000216 AC: 3AN: 1388748Hom.: 0 Cov.: 30 AF XY: 0.00000146 AC XY: 1AN XY: 686474
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152224Hom.: 0 Cov.: 33 AF XY: 0.0000537 AC XY: 4AN XY: 74420
ClinVar
Submissions by phenotype
Glycogen storage disease XV;C4015452:Polyglucosan body myopathy type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 09, 2023 | This sequence change affects a donor splice site in intron 1 of the GYG1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GYG1 are known to be pathogenic (PMID: 20357282, 25272951). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with GYG1-related conditions. ClinVar contains an entry for this variant (Variation ID: 666973). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Polyglucosan body myopathy type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 30, 2018 | The c.7+1G>A variant in GYG1 has not been previously reported in individuals wit h Polyglucosan body myopathy, but has been identified in 1/25088 Latino chromoso mes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org ; dbSNP rs949456055). Although this variant has been seen in the general populat ion, its frequency is low enough to be consistent with a recessive carrier frequ ency. This variant occurs in the invariant region (+1) of the splice consensus s equence and is predicted to cause altered splicing leading to an abnormal or abs ent protein. Another variant at this splice junction, c.7G>C, was found as compo und heterozygous with a second GYG1 variant in an individual with Polyglucosan b ody myopathy, and for which RNA analysis demonstrated loss of expression. Loss o f function of the GYG1 gene is an established disease mechanism in autosomal rec essive Polyglucosan body myopathy. In summary, although additional studies are r equired to fully establish its clinical significance, this variant is likely pat hogenic. ACMG/AMP Criteria applied: PVS1_Strong; PM2. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at